Search Results for "Rituximab Patent"

00:34 EDT 25th July 2017 | BioPortfolio

Matching Channels

CD20 Antibodies

The chimeric anti-CD20 antibody rituximab (Rituxan & MabThera) from Biogen Idec and Genentech/Roche is one of the world’s commercially most successful antibodies (2007 sales of over US$ 5 bl...

Biosuperior Antibodies

After biosimilar versions of therapeutic proteins have become reality in Europe and in the US, now it’s the turn of therapeutic antibodies to be in the line of fire. Patents of the first wave of...


India, in the Asian subcontinent is the world’s fourth largest producer of pharmaceuticals, and is thought as one of the most promising biotech markets in the world. Several important steps ...

Tumor Necrosis Factor TNF Products

Tumor Necrosis Factor (TNF) and TNF receptor antagonists and agonists used to treat TNF-mediated inflammatory diseases such as rheumatoid arthritis or to treat cancer. TNF blockers are the commerc...

Matching News

Celltrion and Teva set to take lead in US rituximab biosimilars

Celltrion and Teva look set to get a biosimilar of Roche’s blockbuster MabThera/Rituxan (rituximab) onto the US market ahead of rivals. Rituximab went off patent in the US last year, leaving it op...

Genentech's subcutaneous rituximab approved in US

The FDA has approved Genentech’s subcutaneous version of the cancer drug rituximab, allowing for a more convenient injection lasting minutes, rather than several hours. Branded as Rituxan Hycela, s...

Rituximab Biosimilar Shows Clinical Equivalence (CME/CE)

(MedPage Today) -- Multicenter study compared both European and U.S. rituximab originators

Biocad expects Indian approval of rituximab biosimilar soon

India’s Central Drugs Standard Control Organization (CDSCO) has recommended AcellBia, the first rituximab…

Rituximab seen as not effective for symptoms of Sjögren’s Syndrome

Rituximab was not effective for relief of symptomatic fatigue and oral dryness in patients with Sjögren’s Syndrome, according to a recently published analysis.“Although there did not appear to be...

Subcutaneous Rituximab May Soon Be Approved for Certain Blood Cancers

A new study is suggesting that intravenous and subcutaneous rituximab share similar efficacy and safety profiles.

Rituximab is not effective for the treatment of fatigue in primary biliary cholangitis

Results from the RITPBC trial demonstrated that rituximab was not effective for treatment of fatigue in unselected patients with primary biliary cholangitis (PBC). The study, presented at The Internat...

Rituximab for Myasthenia Gravis

In uncontrolled, observational case series, rituximab treatment for myasthenia gravis appears to be effective and safe, but more studies are needed for confirmation.

Matching PubMed Articles

Patent highlights June-July 2016.

A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.

Rituximab-induced lung disease.

Pulmonary toxicity is a rare complication of Rituximab therapy. Although Rituximab is relatively safe and can be administered in an outpatient setting, Rituximab-associated lung disease has been repor...

A novel classification method for aid decision of traditional Chinese patent medicines for stroke treatment.

Traditional Chinese patent medicines are widely used to treat stroke because it has good efficacy in the clinical environment. However, because of the lack of knowledge on traditional Chinese patent m...

Rituximab maintenance therapy for patients with diffuse large B-cell lymphoma: A meta-analysis.

The addition of rituximab to standard chemotherapy has significantly improved survival in patients with lymphoma. Recently, maintenance therapy with rituximab has been shown to prevent relapse and pro...

Rituximab response in follicular lymphoma is associated with the rs20575 polymorphism in TRAILR1 extrinsic apoptosis trigger.

Rituximab in combination with chemotherapy has been proven to increase progression-free and overall survival in follicular lymphoma (FL), but there is considerable interindividual variability in the r...

Search Whole site using Google

Quick Search
Advertisement Advertisement